Long-acting Insulin, Mealtime Insulin Management, Fast-acting Pen-based Insulin, And Oral Diabetes Medications

Published on July 15, 2014

The recent FDA approval of Afrezza, an inhaled insulin, could open up new options in mealtime insulin management for type 1 and type 2 diabetics, reports Health Day.
After being up for approval two previous times, the drug has now passed safety inspections that indicate Afrezza’s efficacy and safet…